Elevated LDL-C is a well-established causal factor in the development and progression of atherosclerotic cardiovascular disease (ASCVD). While current guidelines endorse aggressive LDL-C lowering and define treatment thresholds, many patients remain above recommended targets, highlighting the need for timely monitoring and therapy escalation beyond statins. Join us for a live, interactive TheraTalk session with an expert panel of nationally recognized lipid specialists as they review the latest guideline recommendations, pivotal evidence, and evolving strategies for LDL-C management. Through dynamic case-based discussion, the faculty will explore practical approaches to nonstatin therapy selection, tailoring treatment to patient-specific needs and supporting adherence to achieve optimal risk reduction. Don't miss this opportunity to engage with clinical experts, participate in real-time polling, and get your questions answered in a case-driven forum designed to provide actionable strategies for optimizing LDL-C management in your practice.